Last reviewed · How we verify
NCT06568328
Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD
Phase 1 trial testing Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) in Graft vs Host Disease in 17 participants. Currently enrolling.
1 January 2026
Quick facts
| Lead sponsor | Fujian Medical University |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 17 |
| Start date | 1 September 2024 |
| Primary completion | 1 January 2026 |
| Estimated completion | 31 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) — full drug profile →
Conditions studied
- Graft vs Host Disease — all drugs for Graft vs Host Disease →
Sponsor
Fujian Medical University
Who can join
Adults 1 to 70, any sex, with Graft vs Host Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with steroid-refractory/resistant or steroid-dependent GVHD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06568328
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
Trials testing the same drug.
- NCT06751134 — Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma · Phase 1 · recruiting
- NCT06750133 — Universal CNK-UT Therapy for Refractory aGVHD · Phase 1 · recruiting
Other recruiting trials for Graft vs Host Disease
Currently open trials in the same condition.
- NCT07184853 — Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD · NA · recruiting
- NCT05531786 — Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) Af · Phase 1, PHASE2 · recruiting
- NCT04044365 — Pediatric cGVHD Symptom Scale · recruiting
- NCT02105766 — Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Bet · Phase 2 · active not recruiting
- NCT00106925 — Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants · recruiting
Other Fujian Medical University trials
Trials by the same sponsor.
- NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
- NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
- NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
- NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06568328 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
- Last refreshed: 23 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06568328.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing